Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

<p class="MsoNormal">Featuring an interview with Dr Aaron Lisberg<span class="normaltextrun">,</span> including the following topics:</p> <ul> <li>Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) <ul> <li>Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;<a href= "https://www.annalsofoncology.org/article/S0923-7534(24)04712-4/fulltext" target="_blank" rel="noopener">Abstract LBA7</a></li> <li>Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. <em>J Thorac Oncol </em>2025;[Online ahead of print]. <a href= "https://pubmed.ncbi.nlm.nih.gov/40516821/" target="_blank" rel= "noopener">...